logo
Plus   Neg
Share
Email

Astellas Pharma To Buy Audentes Therapeutics In $3 Bln Deal

Astellas Pharma Inc agreed to acquire Audentes Therapeutics Inc. (BOLD) for US$60.00 per share in cash, representing a total equity value of about US$3 billion.

The offer price represents a premium of 110% to Audentes' closing share price of US$28.61 on December 2, 2019.

Asilomar will commence a tender offer for all outstanding shares of common stock of Audentes. The Tender Offer period is expected to commence in the next few weeks and to expire 20 business days after its commencement, unless otherwise extended.

Astellas said it is still reviewing the impact of a consummation of the transaction on its financial results for the fiscal year ending March 31, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Airbnb has introduced few new rules to control parties and nuisances amidst the backlash the service received after the Halloween shooting at an Airbnb rental in a San Francisco. San Francisco-based Airbnb said it is banning "open invite" parties at all of its accommodations. The company is also banning... The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director... Shares of Upscale furniture chain RH (RH) are on a tear, on the heels of an upbeat annual forecast. Today, the stock set a new all-time high of $239.88.The stock is up more than 20% from its Dec 3 opening price of $196.66, and currently trading at $237.8, and nearly three-times its 52-week low of $84.11....
Follow RTT
>